Paradase for the Treatment of Parainfluenza
Paradase is an investigational host directed antiviral which has shown strong in vitro antiviral activities against parainfluenza infection.
Under EIND’s, over 65 critically ill patients have been treated with Paradase
A phase 1 study in severe PIV infection has been completed
Paradase is in a randomized Phase 2 trial for the treatment of severe PIV infection
Paradase has the potential to receive breakthrough designation and or Fast Track approval for PIV indication
Treatment of severe PIV is a significant unmet medical need